NOVEL PROTEINS

Abstract: The present invention relates to human diacylglycerol kinase proteins (hDAGK) and particularly to human diacylglycerol kinase beta (hDAGK beta ) protein, and to related nucleotide sequences, expression vectors, cell lines, antibodies, screening methods, compounds, methods of production and methods of treatment, as well as other related aspects.

Description: Novel Proteins Field of the Invention The present invention relates to human diacylglycerol kinase proteins (hDAGK) and particularly to human diacylglycerol kinase β (hDAGKβ) protein, and to related nucleotide sequences, expression vectors, cell lines, antibodies, screening methods, compounds, methods of production and methods of treatment, as well as other related aspects. Background of the Invention Diacylglycerol kinases (DAGKs) are a family of enzymes that convert diacylglycerol (DAG) to phosphatidic acid and are therefore known to attenuate DAG-dependent protein kinase C activation (PCK) (1 ). Five types of DAGKs have been described. Type I DAGKs contains four conserved regions, the N-terminal region (C1 ), two sets of EF-hand motifs (C2), two cysteine-rich zinc finger like structures (C3) and the C- terminal region (C4). Type II isoenzymes contain a pleckstrin homology (PH) domain at the N-terminus. Type III contains only the zinc finger (C3) and the catalytic region (C4). Type IV contains four ankyrin repeats near the carboxyl terminus. Type V contains three instead of two zinc finger structures, a proline-rich region and a PH domain with an overlapping Ras-associating (RA) domain. All share two domains, the C2 and the C3 (2). A 90 kDa DAGKβ (3) belonging to type I was found by screening a rat brain cDNA library using fragments of rat a DAGK cDNA under low stringency conditions. The cDNA clone obtained was completely sequenced. The rat DAGKβ cDNA has an open reading frame of 5927 nucleotides and encodes for a protein of 801 amino acids with a predicted relative molecular mass of 90,000. Analysis of the amino acid sequence identified 2 EF-hand motifs (aa 152-180 and 197-225), of two cysteine-rich zinc-finger-like sequences (aa 257-292 and 319-356), and putative ATP-binding sites (aa 266-294 and 533-560). Brain expression has been described for the known DAGK isoforms (2), which include DAGKα, DAGKη, DAGKζ and DAGKΘ. A particular distribution restricted to specific regions of the central nervous system (CNS) was described for the DAGKβ form, originally identified in the rat (90Da DAGKβ). The rat beta form is predominantly localised in neurons of the caudate-putamen, the accubens nucleus and the olfactory tubercle. Such brain regions are among the main CNS dopaminergic, serotonergic, acetylchoiinergic and glutamatergic terminal fields (4). It has also been demonstrated that some metabotropic dopamine, serotonin, glutamate, acetylcholine and several peptide receptors are coupled with the phosphoinositide signal transduction system (5). Lithium is known as one of the most effective therapies for bipolar disorders. Although the biological mechanisms of the mood stabilising properties of lithium are not well understood, experimental evidence indicates that lithium modulates the phosphoinositide signal transduction system (6) by inhibiting the phosphatase that liberates inositol from inositol phosphate (IP), and by modifying the activity of the phospholipase C (PLC)-dependent signalling pathways, including the levels of the second messenger diacylglycerol (DAG) that activates protein kinase C (PKC). With this background in mind, the present inventors have determined that the DAGKs, and particularly the human ortholog of rat 90kDa DAGKβ (hDAGKβ) and variants thereof will provide targets for the development of novel mood stabilising agents and therapeutic agents for treatment of other disorders. Clearly there is a need for proteins and related nucleotide sequences that may be used to screen for mood stabilising agents and which may also play a role in preventing, ameliorating or correcting mood disorders and dysfunction and other neurological diseases. Accordingly, it is an object of the present invention to identify targets for screening of novel therapeutic agents. It is another object of the invention to locate and characterise human DAGKβ and variants thereof. Other objects of the present invention will become apparent from the following detailed description thereof. Summary of the invention According to one embodiment of the present invention there is provided an isolated human diacylglycerol kinase β (hDAGKβ) protein or a variant thereof. In a particularly preferred embodiment of this invention the human diacylglycerol kinase β (hDAGKβ) has the amino acid sequence set out in Seq ID No 1 or Seq ID No 4. The hDAGKβ protein having the amino acid sequence set out in Seq ID No 4 is referred to as SV- hDAGKβ protein. According to one embodiment of the present invention there is provided a nucleotide sequence encoding a human diacylglycerol kinase β (hDAGKβ) protein or a variant thereof, or a nucleotide sequence that is complementary thereto. In a particular preferred embodiment of the invention the polynucleotide comprises the sequence set out in Seq ID No 3 or Seq ID No 6. The hDAGKβ protein having the polinucletide sequence set out in Seq ID No 6 is referred to as SV-hDAGKβ protein. In accordance with another aspect of the invention there is provided an expression vector comprising a nucleic acid sequence as referred to above which is capable of expressing a hDAGKβ protein. According to a further aspect of the invention there is provided a stable cell line comprising an expression vector as referred to above. Preferably the cell line is a modified HEK293T, CHO, HeLa, Sf9 or COS cell line. According to yet a further aspect of the invention there is provided an antibody specific for a hDAGKβ protein. According to still another aspect of the invention there is provided a method for identification of a compound that exhibits DAGK modulating activity, comprising contacting a DAGK protein with a test compound and detecting modulation of enzyme activity or detecting enzyme inactivity. Preferably the DAGK is hDAGKβ or a variant thereof . According to another aspect of the invention there is provided a compound which modulates hDAGK activity, identifiable by the method referred to above. Preferred compounds according to the present invention are those that modulate hDAGKβ activity or a variant thereof. According to another aspect of the invention there is provided a compound that modulates hDAGK activity. Preferred compounds according to the present invention are those that modulate hDAGKβ activity or a variant thereof. According to a further aspect of the invention there is provided a method of treatment or prophylaxis of a disorder that is responsive to modulation of hDAGK activity in a human patient, which comprises administering to said patient an effective amount of a compound as referred to above. Conveniently the hDAGK is hDAGKβ or a variant thereof . Preferably the disorder is a mood disorder, epilepsy, a neurodegenerative disorder, anxiety, schizophrenia, migraine, drug dependence, stroke, Alzheimer's dementia or Parkinson's disease. According to a further aspect of the invention there is provided a method of treatment or prophylaxis of a disorder that is responsive to modulation of hDAGK activity in a human patient which comprises administering to said patient an effective amount of a modulator of hDAGK activity. Conveniently the hDAGK is hDAGKβ or a variant thereof . Preferably the disorder is a mood disorder, epilepsy, a neurodegenerative disorder, anxiety, schizophrenia, migraine, drug dependence, stroke, Alzheimer's dementia or Parkinson's disease. According to another aspect of the invention there is provided use of a compound as referred to above in a method of formulating a medicament for treatment or prophylaxis of a disorder that is responsive to modulation of hDAGK activity in a human patient. Conveniently the hDAGK is hDAGKβ or a variant thereof . Preferably the disorder is a mood disorder, epilepsy, a neurodegenerative disorder, anxiety, schizophrenia, migraine, drug dependence, stroke, Alzheimer's dementia or Parkinson's disease. According to another aspect of the invention there is provided use of a modulator of hDAGK activity in a method of formulating a medicament for treatment or prophylaxis of a disorder that is responsive to modulation of hDAGK activity in a human patient. Conveniently the hDAGK is hDAGKβ or a variant thereof . Preferably the disorder is a mood disorder, epilepsy, a neurodegenerative disorder, anxiety, schizophrenia, migraine, drug dependence, stroke, Alzheimer's dementia or Parkinson's disease. According to another aspect of the invention there is provided a method of producing a hDAGKβ protein or a variant thereof comprising introducing into an appropriate cell line a suitable vector comprising a nucleotide sequence encoding for a hDAGKβ protein or a variant thereof, under conditions suitable for obtaining expression of the hDAGKβ protein or variant. Seq ID No 3 shows the complete nucleotide sequence of the human DAGKβ. Seq ID No 5 shows the complete nucleotide sequence of the SV-hDAGKβ . Seq ID No 1 shows the nucleotide and encoded amino acid sequence of the human DAGKβ sequence. Seq ID No 4 shows the nucleotide and encoded amino acid sequence of the SV-hDAGKβ . Seq ID No 7 shows pairwise alignment of hDAGKβ and SV- hDAGKβ full-length amino acids sequences with rat homologue. The following drawings are illustrative of embodiments of the invention and are not meant to limit the scope of the invention as encompassed by the claims. Figure 1 shows a reverse transcriptase polymerase chain reaction (RT- PCR) of human adult and human foetal brain (polyA+RNA). Figure 2 shows the position of the alternatively spliced exons that generate a family of hDAGKβ transcripts. The alternatively spliced exons are illustrated as white boxes. The dashed box identifies the SV- hDAGKβ transcripts. Panel A: hDAGKβ transcripts generated through alternative splicing. Panel B: SV-hDAGKβ transcripts generated through alternative splicing. Figure 3 shows RT-PCR analysis of the expression of hDAGKβ and SV- hDAGKβ in human tissue cDNAs. PCR reactions were carried out separately for each primer pair (hDAGKβ, SV-hDAGKβ and β-actin control) on the indicated tissue cDNAs, and reactions corresponding to the same tissue template were loaded in the same well. Figure 4 shows RT-PCR analysis of hDAGKβ and SV- hDAGKβ expression in normal and Alzheimer cerebellum, β-actin was used as a control of RNA levels in the samples. Detailed Description of the Invention Throughout the present specification and the accompanying claims the words "comprise" and "include" and variations such as "comprises", "comprising", "includes" and "including" are to be interpreted inclusively. That is, these words are intended to convey the possible inclusion of other elements or integers not specifically recited, where the context allows. As referred to above, the present invention relates to human diacylglycerol kinase β (hDAGKβ) protein, sequence information for which is provided in Seq ID No 1 or Seq ID No 4. In the context of this invention the term "isolated" is intended to convey that the protein is not in its native state, insofar as it has been purified at least to some extent or has been synthetically produced, for example by recombinant methods. The term "isolated" therefore includes the possibility of the protein being in combination with other biological or non-biological material, such as cells, suspensions of cells or cell fragments, proteins, peptides, organic or inorganic solvents, or other materials where appropriate, but excludes the situation where the protein is in a state as found in nature. Routine methods can be employed to purify and/or synthesise the proteins according to the invention. Such methods are well understood by persons skilled in the art, and include techniques such as those disclosed in Sambrook et al. (7), the disclosure of which is included herein in its entirety by way of reference. By the term "variant" what is meant throughout the specification and claims is that other peptides or proteins which retain the same essential character of the diacylglycerol kinase for which sequence information is provided, are also intended to be included within the scope of the invention. For example, other peptides or proteins with greater than about 80%, preferably at least 90% and particularly preferably at least 95% homology with the sequences provided are considered as variants of the enzymes. Such variants may include the deletion, modification or addition of single amino acids or groups of amino acids within the protein sequence, as long as the peptide maintains the biological functionality of a hDAGKβ. The rat DAGKβ protein is of course excluded from the definition of "variant". Human DAGKβ is expressed in human brain and has the highest (-95% identity) sequence homology with the rat DAGKβ. Therefore, hDAGKβ is likely to be the human orthologue of rat DAGKβ. Seq ID No 1 reveals a 3926 bp (base pair) open reading frame which encodes an 804 amino acid protein . This deduced protein sequence is -95 % identical to the rat DAGKβ and shares many of its characteristics and all the domains. The invention also includes nucleotide sequences identified as Seq ID No 1 or Seq ID No 4 that encode for hDAGKβ protein or variants thereof as well as nucleotide sequences that are complementary thereto. Preferably the nucleotide sequence is a DNA sequence and most preferably, a cDNA sequence. Such nucleotides can be isolated or synthesised according to methods well know in Sambrook et al. (7), the disclosure of which is included herein in its entirety by way of reference. The present invention also includes expression vectors that comprise nucleotide sequences encoding for the hDAGKβ protein or variants thereof. A further aspect of the invention relates to an expression vector comprising nucleotide sequences encoding for hDAGKβ protein or variants thereof. Such expression vectors are routinely constructed in the art of molecular biology and may for example involve the use of plasmid DNA and appropriate initiators, promoters, enhancers and other elements, such as for example polyadenylation signals which may be necessary, and which are positioned in the correct orientation, in order to allow for protein expression. Suitable vectors would be apparent to persons skilled in the art. By way of further example in this regard we refer to (7), the disclosure of which is included herein in its entirety. The invention also includes cell lines that have been modified to express the novel protein and variants thereof. Such cell lines include transient, or preferably stable higher eukaryotic cell lines, such as mammalian cells or insect cells, lower eukaryotic cells, such as yeast or prokaryotic cells such as bacterial cells. Particular examples of cells that have been modified by insertion of vectors encoding for the proteins according to the invention include the mammalian HEK293T, CHO, HeL-a, Sf9 and COS cells. It is also possible for the protein and variants thereof of the invention to be transiently expressed in a cell line, such as for example in a baculovirus expression or in an E.coli system. Such systems, which are adapted to express the proteins according to the invention, are also included within the scope of the present invention. According to another aspect, the present invention relates to antibodies (either polyclonal or preferably monoclonal antibodies) which have been raised by standard techniques and are specific for the protein or variants thereof according to the invention. Such antibodies could for example, be useful in purification, isolation or screening involving immuno- precipitation techniques and may be used as tools to further elucidate protein function, or indeed as therapeutic agents in their own right. Antibodies may also be raised against specific epitopes of the proteins according to the invention. An important aspect of the present invention is the use of hDAGK proteins in screening methods designed to identify compounds which act as enzyme iigands and which may be useful as modulators of enzymatic activity. In general terms, such screening methods will involve contacting the hDAGK protein concerned, which may be any known or as yet unrecognised hDAGK protein or variant thereof, preferably hDAGKβ, with a test compound and then detecting modulation of the enzymatic activity, or indeed detecting enzyme inactivity, which results. The present invention also includes within its scope those compounds, which are identified as possessing useful hDAGK modulation activity. Such activity can be determined by the screening methods referred to above. The screening methods comprehended by the invention are generally well known to those skilled in the art. An example of such an approach is provided in the experimental section of this specification. Another aspect of the present invention is the use of compounds which have been identified by screening techniques referred to above, or other compounds found to exhibit hDAGK modulating activity, in the treatment or prophylaxis of disorders that are responsive to modulation of a hDAGK activity, particularly hDAGKβ activity, in a human patient. By the term "modulation" what is meant is that there will be either agonism or antagonism of the enzymatic activity, which results from ligand binding of the compound at the catalytic or regulatory sites of the hDAGK protein. These proteins have been implicated in disorders of the central nervous system (CNS), and therefore, modulation of hDAGK enzymatic activity in these tissues will result in a positive therapeutic outcome in relation to such disorders. In particular, the compounds which will be identified using the screening techniques according to the invention will have utility for treatment and/or prophylaxis of disorders such as mood disorders, epilepsy, anxiety, schizophrenia, drug dependence, neurodegenerative disorders. Some specific examples of disorders which may be treated or prevented by administration of compounds identified in the screening techniques according to the present invention are unipolar and bipolar depression, stroke, Alzheimer's dementia, Parkinson's disease, smoking cessation, and ethanol, nicotine, cocaine and heroine abuse. It is to be understood, however, that the mention of such disorders is by way of example only, and is not intended to be limiting on the scope of the invention. The compounds which are identified according to the screening methods outlined above may be formulated with standard pharmaceutically acceptable carriers and/or excipients, as is routine in the pharmaceutical art, and as is fully described in Remmington's Pharmaceutical Sciences, Mack Publishing Company, Eastern Pennsylvania, 17th Ed, 1985; the disclosure of which is included herein in its entirety by way of reference. The compounds may be administered via enteral or parenteral routes such as via oral, buccal, anal, pulmonary, intravenous, intraarterial, intramuscular, intraperitoneal, topical or other appropriate administration routes. It will further be appreciated that the amount of a compound of the invention required for use in treatment will vary with the nature of the condition being treated, the route of administration and the age, sex, weight and general condition of the patient, and will ultimately be at the discretion of the attendant physician. In general, however, doses employed for adult human treatment will typically be in the range of between about 2mg to about 800mg per day. The present invention will be further explained, by way of example, in the following experimental section. Experimental Identification of human genomic sequences corresponding to bipolar patients' ESTs obtained by in silico analysis: An extensive search using keywords in both public (GenBank) and private (Incyte) databases resulted in some ESTs annotated as specific for bipolar diseases. Most of GenBank ESTs referred to the Stanley Neurovirology Laboratory (John Hopkins School of Medicine, Baltimore), where they were obtained by subtractive hybridisation of frontal cortex RNA from individuals with bipolar disorder and individuals without psychiatric diseases as controls. A first comparison against dbEST (8) using the Blastn (9) alignment program revealed that most of the bipolar specific ESTs do not correspond to any sequence of known function and no other overlapping ESTs can be found to create contigs and enlarge the sequences. Therefore, in a preliminary analysis only those presenting enough information to proceed with an in silico work were considered, in particular those ESTs that showed 100% identity with a genomic sequence. The genomic sequence identified for the EST-S4 (GenBank ace. n. AF019352) is an unannotated 172-Kb length sequence (GenBank ace. n. AC005039) consisting of 2 contigs, for which the order is not known, interrupted by an N bases gap. A detailed analysis was performed on the whole uncharacterised region with the aim of extracting all the high complexity sub-regions that usually contain coding sequences. The low complexity and highly redundant regions found in portions of the sequence were isolated using the SEG (segment sequences by local complexity) tool (10, 11 ,) and compared against all the available sequence databases to exclude any possible translation. As expected, these low complexity regions corresponded mainly to different families of ALU sequences therefore were masked in the subsequent gene prediction approach. The EST-S4 belongs to a novel human gene orthologue to the rat DAGKβ gene The Blastx alignment program was used to compare the 4Kb genomic region surrounding the EST-S4 region with the amino acid sequences of SwissProt and TREMBL databases. Only some local similarities with a high statistical significance with the rat DAGKβ gene were evidenced and suggest an authentic relationship. To verify if this result was consistent with a possible gene construct an in silico exon trapping method (12) was applied on the AC005039 sequence. GeneMark (13), Xpound (12) and GRAIL (14) exon prediction tools were used to locate the potential coding regions within AC005039. Three exons (a, b and c) were found to be consistent with the same ORF and to correspond to exons 22, 23 and 24 of the rat DAGKβ gene. The region was 32 Kb wide and contained the EST-S4 sequence. Searching the more recent set of public domain nucleotide sequences (New GenBank updates), a partial mRNA sequence of 3742 bp from a human adult brain (KIAA0718, Ace. No. AB018261 ) was found to partially overlap the 4 kb genomic sequence (100% identity with the three exons so far identified). The predicted protein sequence (defined in GenPept as KIAA0718 protein) was limited to 742 aa with a N-terminal truncation described. Homology search in protein databases indicates a high similarity with rat DAGKβ. Chromosomal localisation of the putative hDAGKβ The genomic sequence AC005039 is annotated as an unfinished sequence mapped on chromosome 7. An "In silico" STS (Sequence Tagged Site) content analysis (15) was performed on the sequence, and the 3 STSs (SWSS2950, D7S2174 and sWSS2190) found in the sequence confirmed that the hDAGKβ is localised on 7p21. In silico cloning of full-length of the hDAGKβ mRNA Comparing (tBlastn) the first two exons of the rat protein against the GenBank HTG (high throughput genomic) sequences database, two further overlapping genomic sequences (100% identity) were identified (GenBank ace. n. H_GS120K9 and AC006045). These sequences do not overlap with AC005039 but both contain four STSs (sWSS3226, SWSS822, sWSS2758, and sWSS2091 ) and belong to the same YAC clone (CEPH791 G01 ) where AC005039 is located. These data indicate that the exons identified belong to the hDAGKβ gene and provide the information missing in the KIAA0718 structure to complete the full length sequence of the predicted protein Identification and characterisation of human DAGKβ variants in cDNA libraries. Three DNA probes were used to screen a human foetal brain cDNA library (cat. n. 936206 Stratagene, La Jolla, CA). The 246bp fragment was obtained by reverse transcriptase polymerase chain reaction (RT- PCR) (16) with the oligo pairs previously described (see above paragraph), and used for radioactive hybridisation. The two primer pairs DAGKIAAfor/DAGKIAArev (5' TGAAGACATTCCTGGAAGCC, 5' GACTGTGTACTTGCAGAAGG), and5hDAGKfor/5hDAGKrev (5' CCATGACAAACCAGGAAAAATGG, 5' GATTATACTTTGCAAGCACACC) were used to obtain 2 RT-PCR products of 647 bp and of 151 bp respectively from foetal brain polyA+ RNA (Clontech) (Figure 1 , panel B). The PCR conditions included an initial hot-start at 94°C for 2 minutes, followed by 35 cycles at 94°C for 1 minute, 56°C (DAGKIAAfor/DAGKIAArev) or 58°C (5hDAGKfor/5hDAGKrev) for 1 minute, 72°C for 1 minute and terminated by 7 minutes at 72°C. The resulting PCR amplicons were separated on a 2% agarose gel and used for radioactive hybridisation. To fully sequence the cDNA clones isolated, the library inserts were first subcloned in pBluescript KS vector (Stratagene, LaJolla, CA). After transformation, colonies were screened by hybridisation with the previously described probes. Positive colonies were subjected to direct sequencing (17) using the T3 and T7 primers. The DNA sequences obtained were assembled using the GCG package, translated and aligned with the rat DAGKβ gene using CLUSTAL (18). Two positive clones were isolated using a human DAGKβ-specific probe covering sequences from position 1524 to position 2360 and their sequence covered by sequencing on both DNA strands. The clones contained the last three exons and part of the 3' untranslated region (UTR) of the hDAGKβ sequence. The tissue distribution of hDAGKβ gene was established by radioactive hybridisation on multi-Tissue northern blots (Clontech) according to the manufacturer's recommendations. The probes were obtained by RT- PCR amplification of different portions of the coding region of hDAGKβ including the 3' splice variant specific probe. Identification, characterisation and cloning of the 3' end of SV- DAGKβ splice variant. The GCG package (Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, Wisconsin) was used to align the human genomic sequence surrounding the EST-S4 with the rat 90 kDa DAGKβ mRNA. The EST-S4 is located in the 30 Kb intron between exons b and c. It overlaps with the AC005039 genomic sequence 91 bp downstream the last amino acid of exon b. The genomic sequence contains two in frame stop codons and a possible polyadenylation signal is present on the EST sequence. In order to verify if EST-S4 identifies a splice variant of the human DAGKβ gene, a reverse transcriptase polymerase chain reaction (RT- PCR) using the following primer pair: DAGK7for (5' TGCCAATGCAAATTGATGGG) and DAGK7rev (5' AGCTAAATCATTGCCAAGGG) that span exon b and EST-S4 was performed. The PCR conditions included an initial hot-start at 94°C for 5 minutes, followed by 35 cycles at 94°C for 1 minute, 56°C for 1 minute and 72°C for 1 minute and terminated by 5 minutes at 72°C. The resulting PCR amplicon was separated on a 2% agarose gel and shown to be of 246bp. The transcript was successfully amplified in both human adult and foetal brain polyA÷ RNA (Clontech) RT-PCR reactions. As a control the human genomic DNA was also amplified, yielding a fragment of the same length. The results indicate that the EST-S4 might correspond to the 3'- UTR of a new splice variant (Figure 1 , panel A). Thus the shortest form of hDAGKβ protein encoded by the splice variant transcripts is herein designated as SV-hDAGKβ. In order to further confirm the existence of an alternative splicing event giving rise to a 3' splice variant hDAGKβ isoform a 3' rapid amplification of cDNA ends (RACE) strategy (19) was applied to physically identify and clone the relevant transcript portion in the form of cDNA. Briefly, human foetal brain polyadenyiated RNA was reverse transcribed using the anchor oligonucleotide CCAGTGAGCAGAGTGACGAGGACTCGAGCTCAAGC(T) 17 as a primer for first strand cDNA synthesis. The resulting cDNA was employed as a template for two nested rounds of PCR employing anchor-specific and gene-specific primers (first round RACE: CCAGTGAGCAGAGTGACG and TCAGAGCCACTACATTTAGGT; second round RACE: GAGGACTCGAGCTCAAGC and AGGTTGTAGACATTATATACC). PCR conditions for both rounds were: 94°C for 3 minutes (hot start); 25 cycles of (94°C for 30", 56°C for 30" , 72°C for 30") followed by a 72°C for 10' step. Two RACE products, of 200bp and 750 bp respectively, were obtained and cloned into appropriate E.coli plasmid cloning vectors. Double-pass sequencing confirmed the identity of the two products as two alternatively spliced transcripts bearing the 3' end of the human DAGKβ splice variant coding sequence (with two predicted in-frame translational stop codons at position 2320 and 2365) and ca. 100bp or ca. 650bp (owing to two alternatively used polyadenylation signals) of 3' untranslated sequence (UTR). Thus hDAGKβ splice variant transcripts run out of the penultimate coding exon into the last intron of the DAGKβ locus, terminating at two alternatively used polyadenylation signals. The predicted protein encoded by the splice variant transcripts (Seq ID No 4) lacks the last 30 amino acids present in the longest (direct human orthologue of the rat DAGKβ) variant. Physical cloning of the full length seguence of human hDAGKβ and SV- hDAGKβ cDNAs In order to clone the full length cDNA sequence encoding the two DAGKβ variants, the sequence information derived from the in silico and cloning analyses was employed to design PCR primers comprising the initiation codon of the protein (common to both variants) and the sequence immediately 3' of the predicted translational stop codons of each variant. These primers were employed in two successive rounds of nested long-range PCR (LR-PCR) employing a proofreading thermostable polymerase (XL-PCR kit, Perkin Elmer, CA) according to manufacturer's instructions. First round PCR conditions were as follows: 94°C for 3 minutes (hot start); 35 cycles of (94°C for 30", 55°C for 30", 72°C for 5') followed by a 72°C for 20' step. Second round PCR was carried out on a 1 μl aliquot of a 1 :10 dilution of first round PCR using the same conditions as for first round PCR, except that cycling was for 25 cycles. Primers were as detailed in Table 1. The resulting PCR-amplified products (ca. 2.4kb) were cloned into appropriate plasmid cloning vectors and subjected to double pass sequence analysis. This exercise confirmed the cDNA sequence predicted by the in silico analysis and extended it by revealing the presence of three alternatively spliced exons within hDAGKβ and SV- hDAGKβ transcripts and derived cDNAs (Fig. 5). Alternative transcript splicing generates several isoforms of the hDAGKβ and SV-hDAGKβ Sequence analysis of the cloned full length cDNAs revealed the presence of three alternatively spliced exons (encoding amino acid sequences of 7, 12 and 25 residues respectively) in addition to the previously characterized alternative splicing event leading to the generation of SV-hDAGKβ transcripts (Fig. 2). Thus at least 8 hDAGKβ isoforms and 8 SV-hDAGKβ isoforms are predicted. Expression of hDAGKβ and SV-hDAGKβ transcripts in adult human tissues The specificity of hDAGKβ and SV-hDAGKβ expression in adult human tissues was investigated by RT-PCR. Polyadenyiated RNA for a variety of human tissues was obtained from a commercial source (Clontech, CA). This material was converted to cDNA and a set of PCR primers capable of selectively amplifying either the hDAGKβ or the SV isoform were employed in an RT-PCR study. A set of β-actin specific primers were employed to control the efficacy of the RT-PCR process. Table 1 provides the details of the primers. PCR conditions were: 94°C for 3 minutes (hot start); 40 cycles of (94°C for 30", 56°C for 30" , 72°C for 30") followed by a 72°C for 10' step. The results (Fig. 3) indicate that both hDAGKβ and SV-hDAGKβ are coordinately expressed in all tissues of neuronal origin (brain regions and spinal cord). Non-neuronal tissues (with the exception of the uterus) do not express significant levels of hDAGKβ transcripts. TABLE 1 PCR primers used in the present study. A. PCR primers employed for the amplification of full length hDAGKβ cDNAs. The initiation (start) codon is underlined. B. PCR primers for the analysis of expression of h DAGKβ and SV-hDAGKβ isoforms. Sizes of expected products are indicated. A B Expression of hDAGKβ transcripts in normal vs neuropathological conditions The association between the hDAGKβ and the disorders arising from abnormal expression/activity of hDAGKβ protein and variants thereof can be illustrated by the following experiments. The expression of hDAGKβ transcripts in normal and pathological conditions of relevance to the present patent was initiated by analyzing hDAGKβ expression by RT-PCR in cDNA from the cerebellum of normal individuals and Alzheimer cerebellum. An initial analysis was carried out using a set of hDAGKβ specific and SV-hDAGKβ specific primers and PCR conditions as detailed in the above section. The results (Fig. 4) indicate that expression of hDAGKβ is lost in Alzheimer cerebellum, while expression of SV-hDAGKβ is unchanged. Screening for compounds which exhibit hDAGKβ modulating activity To identify modulators of hDAGK activity (especially hDAGKβ) activity like inhibitors and activators, respectively, a cellular homogenate containing the hDAGK polypeptide (either from cells transfected with the DAGK cDNA or from overproducing organisms) is incubated with substrates (like DAG and ATP) in the absence or the presence of a chemical entity or crude natural extract that might modulate hDAGK activity (primary screening). The activity of the hDAGK polypeptide or a purified preparation of hDAGK polypeptide in the reaction mixture can be quantified by measuring the ATP-dependent phosphorylation of the DAG substrate employing radio-labelled ATP as substrate (20). The labelled product (phosphatidic acid) is extracted into acidified organic solvents and quantitated by scintillation counting. For more accurate determinations the phosphatidic acid product can also be separated from the mixture by TLC methods and the corresponding radioactive bands can be quantified by using a phosphoimager system. Fluorescence or chemiluminescence-tagged DAG can also be used as the substrate for hDAGK. In this case, the PA product will become labelled with the selected probe and can be separated from the substrate donor molecule by TLC and quantified via densitometric analysis of fluorescent or chemoluminescent spots. This application also relates to a method of identifying a compound or a composition that can activate or inhibit the activity of the promoter for the DNA of the present invention, which comprises (i) adding a test compound to a cell line whose hDAGK gene has been inactivated by introducing a reporter gene, e.g., the beta-gaiactosidase from E.coli origin (lacZ); (ii) determining if transcription of the reporter gene occurs by measuring the level of activation of lacZ gene using the chromogenic substrate X-gal using high-throughput colorimetric measurements. The compounds or compositions which are able to inhibit or activate the promoter for the hDAGKβ DNA will alter the expression of the reporter gene. Compounds identified in this way are then tested in vivo to assess their ability to modulate the level of the expression of hDAGK, especially hDAGKβ, in mice CNS. It is to be understood that modifications and/or alterations to the aspects of the invention specifically disclosed within this application, which based upon the disclosure herein would be readily apparent to a person skilled in the art, are also considered to be included within the scope of the invention as outlined in the appended claims. References 1. Sakane F., Kai, M., Wada, I., Imai, S., Kanoh, H. (1996). The C- terminal part of diacylglycerol kinase α lacking zinc fingers serves as a catalytic domain. Biochem. J. 318, 583-590. 2. Sakane, F. and Kanoh, H. (1997). Molecules in focus: diacylglycerol kinase. Int. J. Biochem. Cell Biol, 19, 1139-1143. 3. Goto, K. and Kondo, H. (1993). Molecular cloning and expression of a 90-kDa diacylglycerol kinase that predominantly localizes in neurons. Proc. Natl. Acad. Sci. 90, 7598-7602. 4. Heimer, L, Zahm, D.S., Alheid, G.F. (1995). Basal ganglia. In: G. Paxinos "The rat nervous system" Academic Press, San Diego, pp.579- 628 5. Fisher, S.K., Heacock, A.M., Agranoff, B.W. (1992). Inositol lipids and signal transduction in the nervous system: an update. J. Neurochem. 58,18-38. 6. Yuan, PX, Chen, G., Huang, L.D., Manji, H.K. (1998). Lithium stimulates gene expression through the AP-1 transcription factor pathway. Mol. Brain. Res. 58,225-230. 7. Sambrook, J., Fritsch, E.F. and Maniatis, T. Molecular Cloning: a Laboratory Manual. 2 nd Edition. CSH Laboratory Press. (1989) 8. Boguski, M.S., Lowe, T.M. and Tolstohev, CM. (1993) dbEST: database for 'Expressed Sequence Tags' Nature Genetics, 4, 332-333. 9. Altschul, S.F., Warren, G., Webb, M., Myers, E.W., and Lipman, D.J., (1990). Basic local alignment search tool. J. Mol. Biol, 215, 403-410. 10. Wootton, J.C. and Federhen S.,(1993). Statistics of local complexity in amino acid sequences and sequence databases. Comput. Chem. 17,149-163 11. Wootton, J.C. (1994). Non-globular domains in protein sequences: aoutomated segmentation using complexity measures. Comput. Chem. 18, 269. 12. Kamb, A., Wang, C, Thomas, A., DeHoff, B.S., Norris, F.H., Richardson, K., Rine, J., Skolnick, M.H. and Rosteck Jr., P.R. (1995). Software trapping: a strategy for finding genes in large genomic regions. Comput. Biomed. Res. 28, 140-153. 13. Borodovsky, M. and Mc Ininch J.D., (1993). Parallel gene recognition for both DNA strands. Computers and Chemistry 17, 123-133 14. Uberbacher, E.C., and Mural, R.J., (1991 ). Locating protein-coding regions in Human DNA sequences by a multiple sensors-neural network approach. Proc. Natl. Accad. Sci. USA, 88, 11261 -1 1265 1.5. Schuler, G.D. (1998). Electronic PCR: bridging the gap between genome mapping and genome sequencing. Trends in Biotech. 16, 456- 459. 16 Kawasaki ES. (1990). Amplification of RNA. In: PCR protocols, a guide to methods and applications. Eds Innis, Gelfand, Sninsky and White. Acad. Press. 17. Trower MK., Burt D., Purvis IJ., Dykes CW. & Christodoulou C. (1995). Fluorescent dye-primer cycle sequencing using non-purified PCR products as templates; development of a protocol amenable to high- throughput DNA sequencing. Nucleic Acids Research ,23, 2348-2349 18. Higgins, D.G. and Sharp, P.M. (1988). CLUSTAL: a package for performing multiple sequence alignments on a microcomputer. Gene 73, 237-244. 19 Frohman, MA (1993). Rapid amplification of complementary DNA ends for generation of full-length complementary DNAs: thermal RACE. Methods Enzymol, 218, 340-56 20. Kanoh, H., Sakane, F., Yamada, K. (1992). Diacylglycerol kinase isozymes from brain and lymphoid tissues. Methods Enzymol. 209, 162- 172.

Claims: Claims 1. An isolated human diacylglycerol kinase β (hDAGKβ) protein or a variant thereof. 2. hDAGKβ protein according to claim 1 having an amino acid sequence as set out in Seq ID No 1 or in Seq ID No 4. 3 hDAGKβ protein according to claim 1 having an amino acid sequence as set out in Seq ID No 4. 4. A nucleotide sequence encoding a hDAGKβ protein or a variant thereof, or a nucleotide sequence which is complementary thereto. 5. The nucleotide sequence according to claim 4 having a sequence as set out in Seq ID No 3 or in Seq ID No 6. 6. The nucleotide sequence according to claim 4 having a sequence as set out in Seq ID No 6. 7. The nucleotide sequence according to in any of claims 4 to 6 or which is a cDNA sequence. 8. An expression vector comprising a nucleotide sequence according to any one of claims 4 to 7, which is capable of expressing an hDAGKβ protein. 9. A stable cell line comprising an expression vector according to claim 8. 10 The cell line according to claim 9 that is a modified HEK293, COS or HeLa cell line. 11. An antibody specific for a protein as claimed in any claims 1 to 3. 12. A method for identification of a compound that exhibits DAGK modulating activity, comprising contacting a DAGK protein with a test compound and detecting modulation of enzyme activity or detecting enzyme inactivity. 13. The method according to claim 12 wherein the DAGK protein is hDAGKβ. 14. A compound that modulates hDAGK activity, identifiable by a method according to claim 12. 15. The compound according to claim 14 that modulates hDAGKβ activity. 16. A method of treatment or prophylaxis of a disorder that is responsive to modulation of hDAGK activity in a human patient, which comprises administering to said patient an effective amount of a compound according to either claim 14 or claim 15. 17. A method of treatment or prophylaxis of a disorder that is responsive to modulation of hDAGK activity in a human patient, which comprises administering to said patient an effective amount of a modulator of hDAGK activity. 18. The method according to either claim 16 or claim 17 wherein the disorder is a mood disorder, epilepsy, a neurodegenerative disorder, anxiety, schizofrenia, migraine, drug dependence, stroke, Alzheimer's dementia or Parkinson's disease. 19. The method according to any one of claims 16 to 18 wherein the disorder is responsive to modulation of hDAGKβ. 20. Use of a compound according to either claim 14 or claim 15 in a method of formulating a medicament for treatment or prophylaxis of a disorder that is responsive to modulation of hDAGK activity in a human patient. 21. Use of a modulator of hDAGK activity in a method of formulating a medicament for treatment or prophylaxis of a disorder that is responsive to modulation of hDAGK activity in a human patient. 22. The use according to either claim 20 or claim 21 wherein the disorder is a mood disorder, epilepsy, neurodegenerative disorder, anxiety, schizofrenia, migraine, drug dependence, stroke, Alzheimer's dementia, Parkinson's disease. 23. The use according to any one of claims 20 to 22 wherein the disorder is responsive to modulation of hDAGKβ. 24. A method of producing an hDAGKβ protein or a variant thereof comprising introducing into an appropriate cell line a suitable vector comprising a nucleotide sequence encoding for an hDAGKβ protein or a variant thereof, under conditions suitable for obtaining expression of the hDAGKβ protein or variant.

Inventors: CALDARA FABRIZIO, CARICASOLE ANDREA, SALA CINZIA FELICITA, CALDARA, FABRIZIO, CARICASOLE, ANDREA, SALA, CINZIA, FELICITA
Applicants: CALDARA FABRIZIO, CARICASOLE ANDREA, GLAXO GROUP LTD, SALA CINZIA FELICITA, CALDARA, FABRIZIO, CARICASOLE, ANDREA, GLAXO GROUP LIMITED, SALA, CINZIA, FELICITA
Application year: 1999
Main classification: C12N9
IPC codes: A61K38, A61K45, A61P25, C07K16, C12N5, C12N9, C12N15, C12Q1, G01N33